Detalhe da pesquisa
1.
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Clin Cancer Res
; 26(5): 1000-1008, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31772119